In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2.

ABSTRACT:

Background

The advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provoked researchers to propose multiple antiviral strategies to improve patients' outcomes. Studies provide evidence that cyclosporine A (CsA) decreases SARS-CoV-2 replication in vitro and decreases mortality rates of coronavirus disease 2019 (COVID-19) patients. CsA binds cyclophilins, which isomerize prolines, affecting viral protein activity.

Methods

We investigated the proline composition from various coronavirus proteomes to identify proteins that may critically rely on cyclophilin's peptidyl-proline isomerase activity and found that the nucleocapsid (N) protein significantly depends on cyclophilin A (CyPA). We modeled CyPA and N protein interactions to demonstrate the N protein as a

SUBMITTER: Laurie K 

PROVIDER: S-EPMC8083350 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature